<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01228019</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-119</org_study_id>
    <nct_id>NCT01228019</nct_id>
  </id_info>
  <brief_title>Niacin (+) Laropiprant (TREDAPTIVE) Re-examination Study (MK-0524A-119)</brief_title>
  <official_title>Re-examination Study for General Drug Use to Assess the Safety and Efficacy Profile of TREDAPTIVE Tablet in Usual Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This survey is being conducted to assess the safety and efficacy of niacin (+) laropiprant
      (TREDAPTIVE) in usual practice in Korea according to the new product re-examination
      regulations of the Korean Food and Drug Administration.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    In HPS2-THRIVE, MK-0524A did not meet the primary efficacy objective and there was a
    significant increase in incidence of some types of non-fatal SAEs
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Any Adverse Experience</measure>
    <time_frame>From start of treatment through 14 days after the last dose (Up to 26 weeks)</time_frame>
    <description>An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the study drug, was also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Adverse Drug Reactions</measure>
    <time_frame>From start of treatment through 14 days after the last dose (Up to 26 weeks)</time_frame>
    <description>An adverse drug reaction was an adverse event of which the relationship to the study drug could not be ruled out. An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the study drug, was also an adverse event.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Cholesterol at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum cholesterol levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum LDL-C levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum HDL-C levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Triglycerides at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Serum triglyceride levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Total Cholesterol at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Serum cholesterol levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Serum LDL-C levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Serum HDL-C levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Triglycerides at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>Serum triglyceride levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's Overall Efficacy Evaluation at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>The investigator evaluated all available data after 12 weeks of TREDAPTIVE and assigned an overall evaluation of &quot;Improved&quot;, &quot;Unchanged&quot; or &quot;Worsened&quot; when compared to baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigator's Overall Efficacy Evaluation at Week 24</measure>
    <time_frame>Baseline and Week 24</time_frame>
    <description>The investigator evaluated all available data after 24 weeks of TREDAPTIVE and assigned an overall evaluation of &quot;Improved&quot;, &quot;Unchanged&quot; or &quot;Worsened&quot; when compared to baseline.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1166</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Mixed Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>All participants</arm_group_label>
    <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacin (+) laropiprant</intervention_name>
    <description>Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label</description>
    <arm_group_label>All participants</arm_group_label>
    <other_name>MK-0524A</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Korean participants with hypercholesterolemia or mixed dyslipidemia treated with niacin (+)
        laropiprant (TREDAPTIVE) for the first time
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants who are treated with TREDAPTIVE tablet within current local label for the
             first time

          -  Participants with primary hypercholesterolemia or mixed dyslipidemia

          -  Participants who are treated with TREDAPTIVE for more than or equal to 24 weeks will
             be included in long-term surveillance

          -  Special participants with known hepatic disorder or renal disorder, participants 65
             years old or older, participants younger than 19 years old, and pregnant woman will be
             evaluated if collected.

        Exclusion Criteria:

          -  Participant who is treated with TREDAPTIVE tablet before contract and out of
             enrollment period

          -  Participant who has a contraindication to TREDAPTIVE tablet according to the current
             local label
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Korea, Republic of</country>
  </removed_countries>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>March 25, 2014</results_first_submitted>
  <results_first_submitted_qc>March 25, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2014</results_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Usual practice re-examination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>1,166 participants who were currently using niacin (+) laropiprant (TREDAPTIVE) for treatment of primary hypercholesterolemia or mixed dyslipidemia were enrolled and their case report forms were collected. Enrollment was stopped early due to termination of all studies involving TREDAPTIVE.</recruitment_details>
      <pre_assignment_details>A completer was considered a participant eligible for safety population. Efficacy population was a sub-population of the safety population</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1166"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="862"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Dose Violation</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Duplicate enrollment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missing pre-treatment data</title>
              <participants_list>
                <participants group_id="P1" count="72"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Triglyceride Entry Criteria Not Met</title>
              <participants_list>
                <participants group_id="P1" count="152"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Violation of Entry Criterion</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics presented for participants in the Safety Population</population>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="862"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.03" spread="10.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="594"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Any Adverse Experience</title>
        <description>An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the study drug, was also an adverse event.</description>
        <time_frame>From start of treatment through 14 days after the last dose (Up to 26 weeks)</time_frame>
        <population>Safety population: all enrolled participants who met entry criteria regarding safety data</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Adverse Experience</title>
          <description>An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the study drug, was also an adverse event.</description>
          <population>Safety population: all enrolled participants who met entry criteria regarding safety data</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="862"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Adverse Drug Reactions</title>
        <description>An adverse drug reaction was an adverse event of which the relationship to the study drug could not be ruled out. An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the study drug, was also an adverse event.</description>
        <time_frame>From start of treatment through 14 days after the last dose (Up to 26 weeks)</time_frame>
        <population>Safety population: all enrolled participants who met entry criteria regarding safety data</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Adverse Drug Reactions</title>
          <description>An adverse drug reaction was an adverse event of which the relationship to the study drug could not be ruled out. An adverse event was any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the study drug, was also an adverse event.</description>
          <population>Safety population: all enrolled participants who met entry criteria regarding safety data</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="862"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Cholesterol at Week 12</title>
        <description>Serum cholesterol levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 12 data for total cholesterol levels.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol at Week 12</title>
          <description>Serum cholesterol levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 12 data for total cholesterol levels.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="301"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.52" spread="32.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
        <description>Serum LDL-C levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 12 data for LDL-C levels.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 12</title>
          <description>Serum LDL-C levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 12 data for LDL-C levels.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="274"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.81" spread="29.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
        <description>Serum HDL-C levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 12 data for HDL-C levels.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 12</title>
          <description>Serum HDL-C levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 12 data for HDL-C levels.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="294"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.06" spread="9.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Triglycerides at Week 12</title>
        <description>Serum triglyceride levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 12 data for triglyceride levels.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides at Week 12</title>
          <description>Serum triglyceride levels were measured at start of treatment (baseline) and after 12 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 12 data for triglyceride levels.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="300"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-106.32" spread="208.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Total Cholesterol at Week 24</title>
        <description>Serum cholesterol levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 24 data for total cholesterol levels and had received TREDAPTIVE for 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Total Cholesterol at Week 24</title>
          <description>Serum cholesterol levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 24 data for total cholesterol levels and had received TREDAPTIVE for 24 weeks</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.01" spread="35.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24</title>
        <description>Serum LDL-C levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 24 data for LDL-C levels and had received TREDAPTIVE for 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) at Week 24</title>
          <description>Serum LDL-C levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 24 data for LDL-C levels and had received TREDAPTIVE for 24 weeks</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.82" spread="30.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24</title>
        <description>Serum HDL-C levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 24 data for HDL-C levels and had received TREDAPTIVE for 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in High Density Lipoprotein Cholesterol (HDL-C) at Week 24</title>
          <description>Serum HDL-C levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 24 data for HDL-C levels and had received TREDAPTIVE for 24 weeks</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.25" spread="8.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Triglycerides at Week 24</title>
        <description>Serum triglyceride levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Participants in safety population whose case report form contained baseline and Week 24 data for triglyceride levels and had received TREDAPTIVE for 24 weeks</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Triglycerides at Week 24</title>
          <description>Serum triglyceride levels were measured at start of treatment (baseline) and after 24 weeks of treatment with TREDAPTIVE</description>
          <population>Participants in safety population whose case report form contained baseline and Week 24 data for triglyceride levels and had received TREDAPTIVE for 24 weeks</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-137.87" spread="153.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator's Overall Efficacy Evaluation at Week 12</title>
        <description>The investigator evaluated all available data after 12 weeks of TREDAPTIVE and assigned an overall evaluation of “Improved”, “Unchanged” or “Worsened” when compared to baseline.</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Participants in safety population whose case report form contained the investigator's overall assessment after 12 weeks of treatment with TREDAPTIVE</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Overall Efficacy Evaluation at Week 12</title>
          <description>The investigator evaluated all available data after 12 weeks of TREDAPTIVE and assigned an overall evaluation of “Improved”, “Unchanged” or “Worsened” when compared to baseline.</description>
          <population>Participants in safety population whose case report form contained the investigator's overall assessment after 12 weeks of treatment with TREDAPTIVE</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Investigator's Overall Efficacy Evaluation at Week 24</title>
        <description>The investigator evaluated all available data after 24 weeks of TREDAPTIVE and assigned an overall evaluation of “Improved”, “Unchanged” or “Worsened” when compared to baseline.</description>
        <time_frame>Baseline and Week 24</time_frame>
        <population>Participants in safety population whose case report form contained the investigator's overall assessment after 24 weeks of treatment with TREDAPTIVE</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Participants with primary hypercholesterolemia or mixed dyslipidemia treated with niacin (+) laropiprant (TREDAPTIVE)</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Overall Efficacy Evaluation at Week 24</title>
          <description>The investigator evaluated all available data after 24 weeks of TREDAPTIVE and assigned an overall evaluation of “Improved”, “Unchanged” or “Worsened” when compared to baseline.</description>
          <population>Participants in safety population whose case report form contained the investigator's overall assessment after 24 weeks of treatment with TREDAPTIVE</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of treatment through 14 days after the last dose (Up to 26 weeks)</time_frame>
      <desc>Safety population: all enrolled participants who met entry criteria regarding safety data</desc>
      <group_list>
        <group group_id="E1">
          <title>ALL PARTICIPANTS</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD GLUCOSE INCREASED</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>UPPER EXTREMITY MASS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>COMMUNICATION DISORDER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="862"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="65" subjects_affected="65" subjects_at_risk="862"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication must be approved by the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study enrollment stopped early due to termination of all TREDAPTIVE studies. Data obtained for participants enrolled prior to termination was analyzed and reported.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

